Dr. Patel discusses the role of biomarker testing in lung cancer, the FDA approvals of amivantamab and mobocertinib in EGFR exon 20 insertion–positive NSCLC, and future research directions in this subset of lung cancer.
Please enable it in your browser's preferences.
You can visit our support center if you're having problems.
We recommend upgrading to the latest
Please check your internet connection and refresh the page. You might also try disabling any ad blockers.